SHSarah Schuman Harlan

Sarah Schuman Harlan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Schuman Harlan has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Carolyn D. Philpott

    Department of Pharmacy Services, UC Health—University of Cincinnati Medical Center, Cincinnati, OH, USA

    2 shared publications
  • Rebecca B. Regen

    Le Bonheur Children's Hospital, Memphis, Tennessee; Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center, Memphis, Tennessee

    2 shared publications
  • Rudy J. Kink

    Le Bonheur Children's Hospital, Memphis, Tennessee; Division of Pediatric Emergency Medicine, Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee

    2 shared publications
  • Alexa Maisenbach

    Prime Saint Joseph Joliet Joliet Illinois USA

    1 shared publication
  • Allyson M. Berg

    Department of Pharmacy, Le Bonheur Children's Hospital, Department of Clinical Pharmacy and Translational Science, The University of Tennessee Health Science Center

    1 shared publication
  • Alyssa Robertson

    Department of Pharmacy WellSpan Health York Hospital York Pennsylvania USA

    1 shared publication

Latest Publications

  • Open Access

    Role of the Emergency Medicine Pharmacist in the Management of Boarding Patients: An Opinion of the Emergency Medicine Practice and Research Network of the American College of Clinical Pharmacy Endorsed by the SAEM Academy of Emergency Medicine Pharmacists and the Society of Emergency Medicine Pharmacists

    by Brian W. Gilbert, David E. Zimmerman, Alyssa Robertson, Gavin D. Jones, Bryan J. Gendron, Jessica L. Corio, Sarah S. Harlan, Kellyn Engstrom, Alexa Maisenbach, Kerry Anne Rambaran, et al.

    As emergency department (ED) crowding and patient boarding reach critical levels nationwide, the role of the emergency medicine pharmacist (EMP) must be both defined and safeguarded. While EMPs are increasingly valued for their contributions to acute care, their responsibilities often unintentionally expand during periods of operational strain, particularly when admitted patients remain in the ED for prolonged durations. EMPs should ideally be resourced to remain focused on time‐sensitive, high‐risk medication management where their expertise is most impactful and not be used as default providers for all pharmacotherapy needs during ED boarding. This perspective outlines our position on the ideal scope of EMP practice during times of congestion, advocating for clearly defined role boundaries, strategic collaboration with other pharmacy team members, and system‐level support to prevent dilution of emergency care. EMPs must be empowered to prioritize critical ED workflows, support resuscitations, and lead initiatives in education, protocol development, and patient safety, without being overextended by responsibilities that can be absorbed by other team members.

  • Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury

    by Sarah Schuman Harlan, Carolyn D. Philpott, Shaun P. Keegan, Molly E. Droege, Aniruddha S. Karve, Brandon Foreman, Devin Wakefield, Eric W Mueller, Kiranpal Sangha, Laura B. Ngwenya, et al.

    Background: Drug pharmacokinetics (PK) are altered in neurocritically ill patients, and optimal levetiracetam dosing for seizure prophylaxis is unknown. Objective: This study evaluates levetiracetam PK in critically ill patients with severe traumatic brain injury (sTBI) receiving intravenous levetiracetam 1000 mg every 8 (LEV8) to 12 (LEV12) hours for seizure prophylaxis. Methods: This prospective, open-label study was conducted at a level 1 trauma, academic, quaternary care center. Patients with sTBI receiving seizure prophylaxis with LEV8 or LEV12 were eligible for enrollment. Five sequential, steady-state, postdose serum levetiracetam concentrations were obtained. Non-compartmental analysis (NCA) and compartmental approaches were employed for estimating pharmacokinetic parameters and projecting steady-state trough concentrations. Pharmacokinetic parameters were compared between LEV8 and LEV12 patients. Monte Carlo simulations (MCS) were performed to determine probability of target trough attainment (PTA) of 6 to 20 mg/L. A secondary analysis evaluated PTA for weight-tiered levetiracetam dosing. Results: Ten male patients (5 LEV8; 5 LEV12) were included. The NCA-based systemic clearance and elimination half-life were 5.3 ± 1.2 L/h and 4.8 ± 0.64 hours. A one-compartment model provided a higher steady-state trough concentration for the LEV8 group compared with the LEV12 group (13.7 ± 4.3 mg/L vs 6.3 ± 1.7 mg/L; P = 0.008). Monte Carlo simulations predicted regimens of 500 mg every 6 hours, 1000 mg every 8 hours, and 2000 mg every 12 hours achieved therapeutic target attainment. Weight-tiered dosing regimens achieved therapeutic target attainment using a 75 kg breakpoint. Conclusion and Relevance: Neurocritically ill patients exhibit rapid levetiracetam clearance resulting in a short elimination half-life. Findings of this study suggest regimens of levetiracetam 500 mg every 6 hours, 1000 mg every 8 hours, or 2000 mg every 12 hours may be required for optimal therapeutic target attainment. Patient weight of 75 kg may serve as a breakpoint for weight-guided dosing to optimize levetiracetam therapeutic target attainment for seizure prophylaxis.


  • Sugammadex Efficacy and Dosing for Rocuronium Reversal Outside of Perioperative Settings

    by Sarah S. Harlan, Carolyn D. Philpott, Madeline J. Foertsch, Sheila C. Takieddine, Nicole J. Harger Dykes

    Background: Sugammadex is approved for postoperative recovery from rocuronium neuromuscular blockade with train-of-four (TOF) guided dosing. Data for non-perioperative sugammadex efficacy and dosing are limited when TOF is not available and reversal is not immediate. Objective: This study evaluated the efficacy, safety, and dose of sugammadex when administered in the emergency department (ED) or intensive care unit (ICU) for delayed rocuronium reversal when TOF guidance was not consistently available. Methods: This single-center, retrospective cohort study included patients over a 6-year period who received sugammadex in the ED or ICU at least 30 minutes after rocuronium administration for rapid sequence intubation (RSI). Patients who received sugammadex for intra-operative neuromuscular blockade reversal were excluded. Efficacy was defined as successful reversal documented in progress notes, TOF assessment, or improvement in Glasgow Coma Scale (GCS). Dose was evaluated in patients with successful reversal by correlating sugammadex and rocuronium dose with reversal time after paralysis. Results: Thirty-four patients were included with 19 (55.9%) patients receiving sugammadex in the ED. Sugammadex indication was acute neurologic assessment in 31 (91.1%) patients. Twenty-nine patients (85.2%) had successful reversal documented. The remaining 5 patients had fatal neurologic injuries with GCS 3 limiting non-TOF efficacy assessment. The median (IQR) sugammadex dose was 3.4 (2.5-4.1) mg/kg administered 89 (56.3-158) minutes after rocuronium. No correlation was identified between sugammadex dose, rocuronium dose, and administration time. No adverse events were noted. Conclusion: This pilot investigation demonstrated safe and effective rocuronium reversal with sugammadex 3 to 4 mg/kg administered in the non-operative setting 1 to 2 hours after RSI. Larger, prospective studies are necessary to determine the safety in patients outside of the operating room when TOF is not available.


  • Intranasal Fentanyl and Midazolam Use in Children 3 Years of Age and Younger in the Emergency Department

    by Jonathan G. Chang, Rebecca B. Regen, Rahul Peravali, Sarah S. Harlan, Matthew P. Smeltzer, Rudy J. Kink


  • Open Access

    Reducing Time to Pain Medication Administration for Pediatric Patients with Long Bone Fractures in the Emergency Department

    by Sarah S. Schuman, Rebecca B. Regen, Lindsay H. Stuart, Camden Harrell, Tamekia L. Jones, Barbara M. Stewart, Allyson M. Berg, Mindy Longjohn, Rudy J. Kink

    Introduction: Pain management is a critical aspect of effective long bone fracture treatment. Pediatric patients frequently report suboptimal pain management, which is an area of growing public concern. The purpose of this quality improvement project was to develop a protocol with the goal to administer pain medication to children presenting with suspected long bone fractures ≤47 minutes of emergency department arrival. Methods: A multidisciplinary team developed a standardized protocol for pain management of patients presenting with musculoskeletal pain utilizing acetaminophen as the first-line agent under a nurse-initiated order. Following education and implementation, weekly reports generated using the International Classification of Diseases codes of fractures were reviewed to assess compliance with the protocol. This study evaluates the frequency of a second pain medication administration and reduction in vital signs and pain scores. Results: Implementation of a pain management protocol reduced median time to pain medication administration to 26 minutes. Overall, 63% (n = 638) of patients required a second pain medication. Of these, 66.5% (348/523) who initially received acetaminophen and 59.7% (286/479) who initially received an opioid required a second pain medication. No significant changes in pre and posttreatment vital signs were found between groups. Patients who initially received opioids experienced a greater reduction in posttreatment pain scores. Conclusions: Using a standardized pain management protocol in combination with comprehensive education effectively reduces median time to pain medication administration in pediatric patients with long bone fractures. Acetaminophen is a rapid and effective first-line agent for managing pain in this population.